Characteristics of Camptothecin 94 patients.AgeCharacteristics<60 (N = 28)≥60 (N = 66)Median age (range)50.5 (20, 59)68 (60, 84)Male (%)16/28 (57%)36/66 (55%)No. Caucasian (%)22/28 (79%)62/66 (94%)Median duration of CR1 (months)12.37.2Charlson comorbidity index 024/28 (86%)34/66 (51%) 13/28 (11%)18/66 (27%) 21/28 (3.0%)11/66 (17%) 30/28 (0.0%)2/66 (3%) 40/28 (0.0%)1/66 (2%)Refractory disease (%)2/28 (7%)23/66 (35%)Therapy-related AML1/28 (4%)10/66 (15%)Antecedent hematologic disorder4/28 (14%)21/66 (32%)Cytogenetic risk score Not available6/28 (21%)22/66 (33%) Good risk5/22 (23%)2/44 (5%) Intermediate risk14/22 (64%)29/44 (65%) Poor risk3/22 (14%)13/44 (30%)Cytarabine dose 3.0 gm/m224/28 (86%)1/66 (2%)Cytarabine dose 2.0 gm/m21/28 (3%)41/66 (62%)Cytarabine dose 1.5 gm/m21/28 (3%)17/66 (26%)Cytarabine dose 1.0 gm/m22/28 (6%)4/66 (6%)>1 cycle of HAMA16/28 (57%)30/66 (45%)Full-size tableTable optionsView in workspaceDownload as CSV
↧